Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057874 · ClinicalTrials.gov registry record · NA
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
A NA study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT02057874 is a NA study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 2 participants.
The verdict
NCT02057874, a NA study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
This pilot clinical trial examines how well different imaging biomarkers acquired using 3-Telsa magnetic resonance imaging (MRI) methods perform in determining treatment response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. Compared to conventional imaging, multi-parametric 3-Tesla MRI offers the ability to quantitatively measure tissue structural, functional, cellular, and molecular properties, providing a more robust, clinically relevant method for assessing cancer response to therapy.
Interventions
- DEVICE 3 Tesla Magnetic Resonance Imaging
- DRUG Magnevist® (Intravenous (IV) administration of MRI contrast agent)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-12-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02057874
The ClinicalTrials.gov registry entry for NCT02057874 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 3 Tesla Magnetic Resonance Imaging is the first listed.
NCT02057874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02057874 about?
NCT02057874 is a clinical study titled "3-Tesla MRI Response to TACE in HCC (Liver Cancer)". This pilot clinical trial examines how well different imaging biomarkers acquired using 3-Telsa magnetic resonance imaging (MRI) methods perform in determining treatment response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. Compared to conventional imaging, mu...
What is the current status of trial NCT02057874?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2014-02. Estimated completion is 2015-12-04.
What interventions are being tested in trial NCT02057874?
The interventions under investigation include: 3 Tesla Magnetic Resonance Imaging (DEVICE), Magnevist® (Intravenous (IV) administration of MRI contrast agent) (DRUG).
Who is sponsoring clinical trial NCT02057874?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.